Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2014

View Archived Issues

Structure-based discovery of novel ITK inhibitors, GNE-9822 lead identified

A potent mGluR5 PAM shows promise in rodent cognition models

Results of a phase I dose-escalation study of a chikungunya virus vaccine

VX-787, first-in-class PB2 influenza polymerase inhibitor

arGEN-X reports preclinical data for ARGX-113

Glenmark Pharmaceuticals to begin IND-enabling studies of new bispecific antibody

Bristol-Myers Squibb and Celgene to evaluate immunotherapy/chemotherapy combination

Amicus Therapeutics reports phase III data for migalastat in Fabry disease

Pfizer and Crohn's & Colitis Foundation of America form IBD collaboration

Aeolus files IND for acute radiation syndrome candidate AEOL-10150

Illumina forms multiple collaborations for oncology genomics analysis

AM-9514, a GK activator with good pharmacokinetic profile in vivo

KalVista Pharmaceuticals confirms first-in-human trial of KVD-001

Potential AD treatment activates TGF-beta signaling pathway in the brain

Vertex Pharmaceuticals patents novel sodium channel blockers

Toyama designs novel antifungal agents

Researchers at Bayer Schering Pharma synthesize new products for cancer

Hanmi Pharm enters into agreement with Luye Pharma Group for poziotinib

Korean scientists present new anti-C5 MAbs

ViaCyte and Janssen enter rights agreement for type 1 diabetes cell therapy

Baxter's PEGylated rFVIII meets primary endpoint in phase III trial

Apixaban granted FDA approval for DVT and PE

EMA accepts Basilea Pharmaceutica's isavuconazole MAA for review

Lilly's ixekizumab superior to etanercept in phase III plaque psoriasis trials

Auxilium and BioSpecifics report positive data from phase IIa trial of Xiaflex

GSK to conduct phase II study of GSK-2862277 to prevent acute lung injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...